GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VYNE Therapeutics
Shares of VYNE Therapeutics, a biopharmaceutical company focused on treating skin diseases, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma skin
VYNE Therapeutics is a pharmaceutical company specializing in the development of treatments for immune-inflammatory skin diseases. We've categorized it as a "Pharma: Skin" stock, and the chart below shows how investors value companies in the stable dermatology sector.
Broad Market Index - GURU.Markets
VYNE Therapeutics is a dermatology company developing drugs for the treatment of immune-inflammatory skin diseases. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how VYNE fits into the overall market dynamics.
Change in the price of a company, segment, and market as a whole per day
VYNE - Daily change in the company's share price VYNE Therapeutics
The daily price change of VYNE Therapeutics Inc. reflects the high volatility inherent in biotech companies. This indicator measures the sensitivity to news about clinical trials of its drugs for the treatment of immunoinflammatory diseases.
Daily change in the price of a set of shares in a market segment - Pharma skin
VYNE Therapeutics specializes in developing drugs to treat skin conditions. Dermatology is a competitive segment of the pharmaceutical industry. The chart below shows the average volatility in this niche, allowing investors to compare VYNE's stock performance with other companies in the sector.
Daily change in the price of a broad market stock, index - GURU.Markets
VYNE Therapeutics is a pharmaceutical company focused on dermatology. Its shares are responding to the success of drug commercialization and clinical trial results. The dynamics of this niche healthcare segment are part of a larger and more diverse picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VYNE Therapeutics
VYNE Therapeutics' year-to-date performance is a story of its transition to developing drugs for immune diseases. Its 12-month market cap depends entirely on clinical trial data for its BET inhibitors. Success in this area could fundamentally transform the company following the sale of its commercial dermatology assets.
Annual dynamics of market capitalization of the market segment - Pharma skin
VYNE Therapeutics is a biopharmaceutical company focused on developing treatments for immunological diseases. This chart shows how its clinical trial successes, partnerships, and focus on this complex area of medicine influence its volatile performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
VYNE Therapeutics, which specializes in the treatment of inflammatory skin diseases, offers new solutions in dermatology. Its annual market capitalization dynamics reflect the commercial potential of its drugs and their ability to compete with existing treatments. Success depends on regulatory approval and physician acceptance.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VYNE Therapeutics
VYNE Therapeutics is a clinical-stage dermatology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its BET inhibitors for the treatment of skin diseases is a key highlight for investors.
Monthly dynamics of market capitalization of the market segment - Pharma skin
VYNE Therapeutics specializes in developing drugs for the treatment of immune-inflammatory skin diseases. The company uses its innovative approach to create new therapeutic approaches. The pharmaceutical sector chart will provide insight into overall investor interest in dermatology, which provides important context for assessing VYNE's scientific and commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
VYNE Therapeutics is a pharmaceutical company specializing in the treatment of inflammatory skin diseases. Its shares move in sync with news about clinical trials and the commercial success of its products. The correlation with overall market trends is minimal, as investors evaluate the potential of specific drugs rather than macroeconomic indicators.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VYNE Therapeutics
VYNE Therapeutics, a dermatology company developing treatments for skin conditions, is at the center of medical news. Its weekly stock price reflects clinical trial results and FDA decisions that determine its ability to bring new products to market.
Weekly dynamics of market capitalization of the market segment - Pharma skin
VYNE Therapeutics specializes in developing drugs for the treatment of skin diseases. Its short-term performance is closely tied to clinical trial results and the commercial success of its products. A comparison with the sector will reveal whether investors are responding to the specifics of dermatology or to general pharmaceutical trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
VYNE Therapeutics is a biotech company developing drugs to treat skin conditions. Its shares are driven by news of clinical trials. The chart shows how their performance is unrelated to overall market trends and sentiment.
Market capitalization of the company, segment and market as a whole
VYNE - Market capitalization of the company VYNE Therapeutics
VYNE Therapeutics' market capitalization chart reflects investor sentiment about its new focus on treating immune-inflammatory diseases. Its performance reflects market confidence in its BET inhibitor platform. Its low valuation is a bet on the success of its early-stage developments, following the company's previous failures in dermatology.
VYNE - Share of the company's market capitalization VYNE Therapeutics within the market segment - Pharma skin
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin diseases. Its market share in the dermatology sector is small, but it is an innovator. Its market capitalization reflects the potential of its patented foam carrier technology for more effective drug delivery.
Market capitalization of the market segment - Pharma skin
This graph shows the total value of the entire pharmaceutical sector focused on skin care. For VYNE Therapeutics, which develops drugs for inflammatory skin diseases, this line demonstrates the scale of the market. The graph's growth reflects the enormous need for new, more effective treatments for conditions like acne and vitiligo.
Market capitalization of all companies included in a broad market index - GURU.Markets
VYNE Therapeutics develops drugs to treat inflammatory skin diseases. Its market capitalization is determined by its dermatology portfolio. Overall, this represents the market share of the business dedicated to making our skin healthier.
Book value capitalization of the company, segment and market as a whole
VYNE - Book value capitalization of the company VYNE Therapeutics
VYNE Therapeutics is a biopharmaceutical company specializing in the treatment of inflammatory skin diseases. Its book value is its financial resources for R&D. This consists of cash that allows the company to develop and test new drugs. How has this capital changed? The chart below shows.
VYNE - Share of the company's book capitalization VYNE Therapeutics within the market segment - Pharma skin
VYNE Therapeutics is a biopharmaceutical company focused on dermatology. Its scientific developments require a physical base: a laboratory for the creation and testing of new drugs for the treatment of skin diseases. The chart shows the company's share of the physical R&D infrastructure in this specific biopharma segment.
Market segment balance sheet capitalization - Pharma skin
VYNE Therapeutics is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. VYNE focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
VYNE Therapeutics' book value is not its product lines, but rather its research platform for developing a new class of anti-inflammatory drugs (BET inhibitors) for the treatment of immune diseases. Its assets reflect its clinical trial capital. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VYNE Therapeutics
VYNE Therapeutics is a dermatology company. Its market value is based on its portfolio of skin treatments. Investors evaluate its ability to successfully commercialize these products and carve out a niche in the large dermatology market.
Market to book capitalization ratio in a market segment - Pharma skin
VYNE Therapeutics is a pharmaceutical company specializing in the treatment of skin diseases. Its valuation on this chart reflects both the sales of its existing products and the potential of its development pipeline. Investors evaluate its ability to compete in the dermatology field.
Market to book capitalization ratio for the market as a whole
VYNE Therapeutics specializes in dermatological drugs. Its valuation is based on the commercial success of existing products and the potential of new developments. This metric helps understand how the market values pharmaceutical companies operating in highly specialized but potentially large markets within the context of the overall economy.
Debts of the company, segment and market as a whole
VYNE - Company debts VYNE Therapeutics
VYNE Therapeutics, a biopharmaceutical company specializing in dermatology, is using capital to fund its clinical development. Following a restructuring and shift in focus, managing cash and debt is a key challenge. This chart shows the company's financial strategy during its transformation.
Market segment debts - Pharma skin
VYNE Therapeutics is a biopharmaceutical company focused on developing novel treatments for inflammatory skin diseases. This chart shows how the development-stage company is raising capital to fund its clinical programs and research, aiming to bring new drugs to market in the competitive field of dermatology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VYNE Therapeutics
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin diseases. Conducting clinical trials and bringing new dermatological products to market requires significant investment. This chart shows how the company uses debt to finance its R&D programs, reflecting the risks of the pharmaceutical industry.
Market segment debt to market segment book capitalization - Pharma skin
VYNE Therapeutics is a pharmaceutical company specializing in the development of drugs for the treatment of skin diseases. Dermatology is a competitive market. This chart shows how the company finances its clinical trials and commercialization. It compares its debt to the market capitalization of the entire pharmaceutical sector.
Debt to book value of all companies in the market
VYNE Therapeutics focuses on developing new treatments for inflammatory skin diseases. Dermatology is a competitive market, and launching a new product requires significant investment. How heavily is the company reliant on debt? This chart of total market debt provides context for assessing its financial strength as it moves toward commercialization.
P/E of the company, segment and market as a whole
P/E - VYNE Therapeutics
VYNE Therapeutics is a biopharmaceutical company focused on developing new treatments for inflammatory skin diseases. This chart shows how investors value its pipeline. The valuation is volatile and depends on the results of clinical trials and the commercial potential of its candidates.
P/E of the market segment - Pharma skin
VYNE Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for inflammatory skin conditions such as acne and rosacea. This chart illustrates the average valuation in the dermatology pharmaceutical sector, where innovative formulas and the ability to meet large market needs are essential.
P/E of the market as a whole
VYNE Therapeutics is a biopharmaceutical company developing new approaches to treating inflammatory skin diseases using its proprietary foam carrier technology. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether VYNE's valuation is based on the potential of its technology platform or is moving in tandem with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VYNE Therapeutics
VYNE Therapeutics develops drugs for the treatment of inflammatory skin diseases. The company uses an innovative approach to creating medications that address unmet patient needs. This schedule reflects market expectations regarding the success of its clinical programs and the commercial potential of new treatments in dermatology.
%20P%2FE%20VYNE%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VYNE-Therapeutics&v=1772683174672 "Chart of the company's future (projected) P/E VYNE Therapeutics")
Future (projected) P/E of the market segment - Pharma skin
VYNE Therapeutics develops drugs for the treatment of inflammatory skin diseases. The company uses its proprietary technology platform to create new drugs. The chart shows future profit forecasts for the sector, helping to understand how investors view the potential of VYNE's dermatology developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772683174696 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
VYNE Therapeutics is a biotech company focused on developing new treatments for inflammatory skin diseases. Its valuation is dependent on the success of clinical trials. This market sentiment chart shows how much investors are prepared to take on the risk associated with investing in dermatological innovations.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772683174701 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VYNE Therapeutics
VYNE Therapeutics is a biopharmaceutical company focused on developing new treatments for inflammatory skin diseases. Its financial performance reflects the costs of clinical trials for its drug candidates. This chart shows the investment in developing innovative dermatological solutions that could generate significant profits if successful.
Profit of companies in the market segment - Pharma skin
VYNE Therapeutics is a biopharmaceutical company developing new approaches to treating inflammatory skin conditions such as acne and rosacea using a proprietary foam delivery technology. This chart shows overall profitability in the dermatology pharmaceutical sector, where ease of use and drug efficacy are key factors in patient and physician choice.
Overall market profit
VYNE Therapeutics is a pharmaceutical company specializing in the development of treatments for skin conditions. Demand for dermatological products is driven by both medical needs and consumers' desire to improve their appearance. This market is less dependent on economic cycles, as can be seen in the chart, than durable goods.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VYNE Therapeutics
VYNE Therapeutics develops proprietary drugs for the treatment of inflammatory skin diseases. The company's future profitability depends on the success of its foam drug delivery technologies and clinical trial results. This chart shows analyst expectations regarding the potential of its dermatology product portfolio.
%20profit%20of%20the%20company%20VYNE%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VYNE-Therapeutics&v=1772683174757 "Graph of future (projected) profit of the company VYNE Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma skin
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin conditions such as acne and rosacea. The company uses a proprietary foam delivery technology to improve drug efficacy. This chart shows revenue projections for the dermatology pharmaceutical segment, providing context for evaluating VYNE Therapeutics' innovations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772683174812 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
VYNE Therapeutics is a pharmaceutical company specializing in the development of treatments for skin diseases. Its revenue depends on the successful commercialization of its products. The overall economic situation, reflected in this chart, affects the ability of patients and the healthcare system to pay, which impacts sales.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772683174818 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VYNE Therapeutics
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin diseases. Revenue from approved products is a key metric. This chart shows how investors assess the market potential of its current products and their confidence in its future developments in dermatology.
P/S market segment - Pharma skin
VYNE Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for inflammatory skin diseases. Their approach is based on a proprietary foam drug delivery technology. This chart reflects the average revenue estimate for the sector, helping to assess the potential of VYNE's innovative platform.
P/S of the market as a whole
VYNE Therapeutics is a pharmaceutical company specializing in the development of drugs for the treatment of inflammatory skin diseases. This chart helps us understand that the valuation of such companies often depends less on current revenue than on the success of clinical trials and the commercial potential of their leading dermatological products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VYNE Therapeutics
VYNE Therapeutics is a pharmaceutical company specializing in the development of drugs for the treatment of inflammatory skin diseases. Estimates based on future revenue are important to the company. They reflect investor expectations for the success of its drug candidates in clinical trials and their commercial potential in the large and competitive dermatology market.
%20P%2FS%20VYNE%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VYNE-Therapeutics&v=1772683174902 "The graph of the company's future (projected) P/S VYNE Therapeutics")
Future (projected) P/S of the market segment - Pharma skin
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin diseases. This chart compares the company's estimated future sales with expectations for the dermatology segment of the pharmaceutical market. It shows how investors view the potential of its new molecules and their ability to offer patients more effective solutions for treating skin conditions.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772683175031 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin diseases. The company's success depends on the results of clinical trials and competition in the dermatology market. This graph of investor expectations reflects their belief that the demand for effective and safe skin treatments will continue to grow.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772683175084 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VYNE Therapeutics
This chart shows the revenue of VYNE Therapeutics, a biopharmaceutical company focused on developing drugs for the treatment of inflammatory skin diseases. Revenue is generated from sales of its commercial products. This growth reflects the success of its drug promotion among dermatologists and the demand for new treatments for skin conditions.
Sales of companies in the market segment - Pharma skin
VYNE Therapeutics develops proprietary foam formulations for the treatment of dermatological conditions. Following the sale of its commercial products, the company is focusing on developing new candidates. Future revenue growth will depend on the success of its innovative technology in treating inflammatory skin conditions.
Overall market sales
VYNE Therapeutics is a pharmaceutical company specializing in the development of treatments for inflammatory skin diseases. Demand for its products is driven by medical needs, but can also be influenced by patients' willingness to spend money on improving their quality of life. This overall economic activity trend indirectly impacts the dermatology market through consumer confidence.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VYNE Therapeutics
VYNE Therapeutics is a biotechnology company developing new approaches to treating immunoinflammatory diseases. The company is focused on BET inhibitors, which have potential applications across a broad range of conditions. Future revenue is dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its innovative platform.
%20sales%20of%20the%20company%20VYNE%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VYNE-Therapeutics&v=1772683175309 "Schedule of future (projected) sales of the company VYNE Therapeutics")
Future (projected) sales of companies in the market segment - Pharma skin
VYNE Therapeutics specializes in developing new treatments for inflammatory skin diseases. This chart shows sales forecasts for the entire dermatology market. Is demand for innovative therapies for conditions like acne or vitiligo growing? This reflects the overall potential of this segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772683175326 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
VYNE Therapeutics is a pharmaceutical company specializing in the development of treatments for dermatological conditions. Demand for its products is driven by medical needs, but some aesthetic procedures may be delayed during the economic downturn. This delay may indirectly impact the cosmetic dermatology segment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772683175377 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VYNE Therapeutics
VYNE Therapeutics develops new approaches to treating inflammatory skin diseases using a proprietary foam drug delivery technology. This chart shows the company's financial trajectory following the commercialization of its products. Profitability depends on sales volumes, competition in the dermatology market, and the continued development of its technology platform.
Market segment marginality - Pharma skin
VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of skin diseases. This metric reflects its financial position at the R&D stage, where profitability is a future goal dependent on the success of clinical trials, regulatory approval, and commercialization of its dermatological products.
Market marginality as a whole
VYNE Therapeutics specializes in developing drugs for the treatment of inflammatory skin diseases. Its success depends on regulatory approval and commercialization of its products. This overall profitability chart reflects the state of the healthcare system and the willingness of insurance companies to cover new dermatological treatments, which is key to market success.
Employees in the company, segment and market as a whole
Number of employees in the company VYNE Therapeutics
VYNE Therapeutics is a biotech company focused on developing new treatments for immune-inflammatory diseases. Its staff consists of scientists working on a new technology platform. This chart shows how the company restructured its team after selling its commercial assets to focus entirely on early-stage research.
Share of the company's employees VYNE Therapeutics within the market segment - Pharma skin
VYNE Therapeutics is a pharmaceutical company specializing in the development of new treatments for inflammatory skin diseases. Its team consists of dermatologists and clinical research specialists. This chart shows the company's market share in the biotech industry, which is an indicator of the scale of its R&D activities in dermatology.
Number of employees in the market segment - Pharma skin
VYNE Therapeutics specializes in developing new treatments for inflammatory skin conditions such as acne and rosacea. This chart shows its presence in the dermatological pharmaceutical sector. The company uses a patented foam delivery technology to improve the efficacy and tolerability of its products.
Number of employees in the market as a whole
VYNE Therapeutics specializes in developing treatments for inflammatory skin diseases. Its success depends on clinical trial results and regulatory approval. This chart shows the overall picture, and VYNE is an example of a biotech company where job creation is directly tied to progress in solving specific medical problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VYNE Therapeutics (VYNE)
VYNE Therapeutics is a biotech company focused on dermatology. Their business is built on R&D and intellectual property. This chart shows how the market values their developments. It reflects market capitalization per employee, which in this sector is a measure of the value of their pipeline and patents in skin treatments.
%20of%20the%20company%20VYNE%20Therapeutics%20(VYNE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VYNE-Therapeutics-VYNE&v=1772683175847 "Chart of market capitalization per employee (in thousands of dollars) of the company VYNE Therapeutics (VYNE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
VYNE Therapeutics (VYNE) focuses on developing new approaches to treating inflammatory skin diseases. In dermatology, this metric reflects the potential of a drug portfolio. A high Score per employee may indicate that the company has identified a unique molecule or mechanism of action that could become a new standard in the treatment of conditions such as acne or psoriasis.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772683175858 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
VYNE Therapeutics is a biotech company developing new approaches to treating inflammatory skin diseases. Its valuation is based on the potential of its proprietary drug delivery technology. The chart shows a high valuation per employee, as investors see promise in developing more effective and patient-friendly drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772683175908 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VYNE Therapeutics (VYNE)
VYNE Therapeutics is a biotech company focused on developing new treatments for immune-inflammatory diseases (dermatology). This graph reflects the R&D stage. A negative loss per employee indicates that the company is actively investing in each of its scientists to advance candidates through clinical trials.
%20Chart%20VYNE%20Therapeutics%20(VYNE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VYNE-Therapeutics-VYNE&v=1772683175911 "Company Profit Per Employee (in thousands of dollars) Chart VYNE Therapeutics (VYNE)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
VYNE Therapeutics specializes in developing treatments for inflammatory skin diseases. In dermatological pharmaceuticals, per-employee value reflects the potential of drugs for a broader market. This graph shows the value each team member generates, allowing one to compare the commercial appeal of their portfolio with that of competitors in the same niche.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772683175928 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
VYNE Therapeutics is a biotech company focused on dermatology. They develop new treatments for inflammatory skin diseases. This is an R&D business. This graph, showing the average market efficiency, provides context for evaluating the biotech model: there is no mass production; all value is created by the intellectual work of a small group of scientists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772683176006 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VYNE Therapeutics (VYNE)
VYNE Therapeutics is a pharmaceutical company specializing in dermatology. This chart shows the commercial effectiveness of their skin treatment products. The growth in revenue per employee demonstrates successful marketing, physician acceptance of their products, and their ability to carve out a niche in a competitive market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VYNE-Therapeutics-VYNE&v=1772683176138 "Sales chart per company employee VYNE Therapeutics (VYNE)")
Sales per employee in the market segment - Pharma skin
VYNE Therapeutics is a biotech focused on dermatology (treatment of skin diseases). They are developing drugs based on their drug delivery platform. This chart shows the average output in the sector. For VYNE, which is in the R&D stage, this is a leading indicator of the effectiveness of personnel costs to advance their developments.
Sales per employee for the market as a whole
VYNE Therapeutics is a biotech company focused on developing a new class of drugs (BET inhibitors) for the treatment of immunoinflammatory skin diseases. Currently, their focus is on R&D. This graph reflects their pre-commercial stage: the company is investing in a team of scientists to advance their candidates through clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company VYNE Therapeutics (VYNE)
VYNE Therapeutics (VYNE) is developing new treatments for inflammatory skin diseases. This chart tracks short positions. Bears may doubt the commercial potential of the company's drugs in the highly competitive dermatology market or bet on failure in key clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VYNE-Therapeutics-VYNE&v=1772683176456 "Short Shares Chart for the Company VYNE Therapeutics (VYNE)")
Shares shorted by market segment - Pharma skin
VYNE Therapeutics (VYNE) is a biotech company developing new treatments for inflammatory skin diseases using BET inhibitors. This chart aggregates short positions in the biotech (dermatology) sector. It reflects investor skepticism about the risks of clinical trials in this competitive field.
Shares shorted by the overall market
VYNE Therapeutics (VYNE) is a clinical-stage biotech. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VYNE Therapeutics (VYNE)
VYNE Therapeutics (VYNE) focuses on developing new treatments for inflammatory skin diseases using proprietary drug delivery technology. This indicator measures the rate of price change. It helps identify when enthusiasm (above 70) about trial data or disappointment (below 30) peaks, signaling a potential reversal.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VYNE-Therapeutics-VYNE&v=1772683176753 "RSI 14 indicator chart for the company's stock VYNE Therapeutics (VYNE)")
RSI 14 Market Segment - Pharma skin
VYNE Therapeutics is a biopharmaceutical company specializing in dermatology. It develops new treatments (including foam technology) for skin conditions. This chart shows the overall sentiment in the skin pharmaceutical sector. It helps us understand whether VYNE's performance reflects its commercial success or a general trend.
RSI 14 for the overall market
VYNE Therapeutics (VYNE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VYNE (VYNE Therapeutics)
VYNE Therapeutics is a biotech company focused on developing a new class of drugs (BET inhibitors) for the treatment of immune-inflammatory diseases. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of the R&D portfolio, particularly in dermatology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VYNE-VYNE-Therapeutics&v=1772683177016 "A chart showing analyst consensus forecasts for the expected stock price. VYNE (VYNE Therapeutics)")
The difference between the consensus estimate and the actual stock price VYNE (VYNE Therapeutics)
VYNE Therapeutics is a biotech company focused on treating immune-inflammatory skin diseases (e.g., vitiligo). This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their R&D pipeline and their chances of success in dermatology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VYNE-VYNE-Therapeutics&v=1772683177130 "A chart showing the difference between the consensus forecast and the actual stock price. VYNE (VYNE Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
VYNE Therapeutics (VYNE) is a biotech company developing BET inhibitors for the treatment of immune-inflammatory diseases (such as vitiligo). This chart shows analysts' overall expectations for the skin pharma sector. It reflects whether experts believe R&D in dermatology is successful or whether they consider the sector overheated.
Analysts' consensus forecast for the overall market share price
VYNE Therapeutics is a biotech company specializing in the development of foam formulations for the treatment of immune-inflammatory skin diseases such as vitiligo. This chart reflects the overall market "risk appetite." For VYNE, a clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VYNE Therapeutics
VYNE is a biotech company that has rebooted itself. Having sold its legacy commercial foam business, they focused entirely on next-generation R&D (oral BTK inhibitors) for the treatment of immune diseases (vitiligo). This chart is a summary indicator of their second chance. It reflects their (speculative) R&D pipeline and their race to keep up with the money.
AKIMA Market Segment Index - Pharma skin
VYNE Therapeutics (VYNE) is a dermatology company specializing in the treatment of inflammatory skin diseases. Their specialty is their foam drug delivery technology (MFT), which is used in their approved acne and rosacea treatments. This chart shows the average index for the segment. It helps investors assess how successful this niche skin pharma strategy is compared to the average.
The AKIM Index for the overall market
VYNE Therapeutics is a biopharmaceutical company developing treatments for immune-inflammatory skin diseases (vitiligo). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this dermatology-focused research company stacks up against overall economic trends.
